Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Beyer

Showing results (181-190 of 225) with videos related to

Pageof 23
Sort By:
Thrombosis and Haemostasis|July 13, 2021
Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-RegistryEdelgard Lindhoff-Last, Ingvild Birschmann, Joachim Kuhn, et al.
Blood|December 24, 2015
Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy useIda Martinelli, Anthonie W A Lensing, Saskia Middeldorp, et al.
Thrombosis Research|June 13, 2016
Low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy: Rationale and design of the Highlow study, a randomised trial of two dosesSuzanne M Bleker, Andrea Buchmüller, Céline Chauleur, et al.
Journal of Thrombosis and Haemostasis : JTH|September 17, 2021
The prognostic value of respiratory symptoms and performance status in ambulatory cancer patients and unsuspected pulmonary embolism; analysis of an international, prospective, observational cohort studyAnthony Maraveyas, Noémie Kraaijpoel, George Bozas, et al.
Chest|September 12, 2018
Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial PopulationPhilip S Wells, Martin H Prins, Jan Beyer-Westendorf, et al.
Chest|June 6, 2016
Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-ExtensionPhilip S Wells, Martin H Prins, Bennett Levitan, et al.
Thrombosis Research|November 26, 2016
Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trialsJan Beyer-Westendorf, Anthonie W A Lensing, Roopen Arya, et al.
Journal of Personalized Medicine|August 26, 2022
Enhancing Anticoagulation Monitoring and Therapy in Patients Undergoing Microvascular Reconstruction in Maxillofacial Surgery: A Prospective Observational TrialTom A Schröder, Henry Leonhardt, Dominik Haim, et al.
Pharmaceuticals (Basel, Switzerland)|November 24, 2022
Pharmacokinetics of Phenprocoumon in Emergency Situations-Results of the Prospective Observational RADOA-Registry (Reversal Agent Use in Patients Treated with Direct Oral Anticoagulants or Vitamin K Antagonists Registry)Edelgard Lindhoff-Last, Ingvild Birschmann, Antonia J Bidenharn, et al.
The Lancet. Haematology|April 1, 2016
Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trialsMartin H Prins, Anthonie W A Lensing, Tim A Brighton, et al.
Pageof 23

Showing results (181-190 of 225) with videos related to

Sort By:
Pageof 23
Thrombosis and Haemostasis|July 13, 2021
Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-RegistryEdelgard Lindhoff-Last, Ingvild Birschmann, Joachim Kuhn, et al.
Blood|December 24, 2015
Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy useIda Martinelli, Anthonie W A Lensing, Saskia Middeldorp, et al.
Thrombosis Research|June 13, 2016
Low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy: Rationale and design of the Highlow study, a randomised trial of two dosesSuzanne M Bleker, Andrea Buchmüller, Céline Chauleur, et al.
Journal of Thrombosis and Haemostasis : JTH|September 17, 2021
The prognostic value of respiratory symptoms and performance status in ambulatory cancer patients and unsuspected pulmonary embolism; analysis of an international, prospective, observational cohort studyAnthony Maraveyas, Noémie Kraaijpoel, George Bozas, et al.
Chest|September 12, 2018
Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial PopulationPhilip S Wells, Martin H Prins, Jan Beyer-Westendorf, et al.
Chest|June 6, 2016
Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-ExtensionPhilip S Wells, Martin H Prins, Bennett Levitan, et al.
Thrombosis Research|November 26, 2016
Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trialsJan Beyer-Westendorf, Anthonie W A Lensing, Roopen Arya, et al.
Journal of Personalized Medicine|August 26, 2022
Enhancing Anticoagulation Monitoring and Therapy in Patients Undergoing Microvascular Reconstruction in Maxillofacial Surgery: A Prospective Observational TrialTom A Schröder, Henry Leonhardt, Dominik Haim, et al.
Pharmaceuticals (Basel, Switzerland)|November 24, 2022
Pharmacokinetics of Phenprocoumon in Emergency Situations-Results of the Prospective Observational RADOA-Registry (Reversal Agent Use in Patients Treated with Direct Oral Anticoagulants or Vitamin K Antagonists Registry)Edelgard Lindhoff-Last, Ingvild Birschmann, Antonia J Bidenharn, et al.
The Lancet. Haematology|April 1, 2016
Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trialsMartin H Prins, Anthonie W A Lensing, Tim A Brighton, et al.
Pageof 23